This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Altria Group has been evolving with the changing industry dynamics. Given the rising health consciousness and stern government regulations to discourage smoking, this tobacco behemoth has been moving beyond traditional cigarettes and expanding in the smokeless category. We note that revenues from the oral product category have been steadily rising on the back of growing popularity for reduced risk products. In this respect, Altria is gaining from the sale of IQOS in United States, through its licensing deal with Phillip Morris. Further, Altria’s investment in Cronos Group highlights its focus on exploring the cannabis market.
Why Altria (MO) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Altria (MO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Altria (MO) is a Top Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Altria (MO) have what it takes? Let's find out.
Top Research Reports for Johnson & Johnson, Visa & Verizon
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Visa (V) and Verizon (VZ).
What FDA's Stance on E-Cigarettes Means for Tobacco Stocks
by Zacks Equity Research
The FDA announces directives to curb e-cigarette usage among youngsters. Though this caused tobacco stocks to gain recently, it is yet to be seen if the upside can be sustained.
Altria (MO) in Focus: Stock Moves 6.7% Higher
by Zacks Equity Research
Altria (MO) was a big mover last session, as the company saw its rise nearly 7% on the day amid huge volumes.
Altria (MO) Shares Up Close to 7% on FDA's Latest Notice
by Zacks Equity Research
The FDA reveals serious enforcement actions related to the marketing and sale of e-cigarettes to minors, which may benefit tobacco players like Altria (MO).
The Zacks Analyst Blog Highlights: JPMorgan, Altria, Charter Communications, Baxter and lululemon
by Tirthankar Chakraborty
The Zacks Analyst Blog Highlights: JPMorgan, Altria, Charter Communications, Baxter and lululemon
Top Research Reports for JPMorgan, Altria & Charter Communications
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan (JPM), Altria (MO) and Charter Communications (CHTR).
Zacks.com featured highlights include: AutoZone, ESCO, Tristate, Altria and Invitation
by Zacks Equity Research
Zacks.com featured highlights include: AutoZone, ESCO, Tristate, Altria and Invitation
5 Top Stocks That Flaunt Superb Earnings Acceleration
by Tirthankar Chakraborty
Studies have shown that a majority of successful stocks have seen acceleration in earnings before an uptick in the stock price.
Altria Hikes Divident by 14.3%, Boosts Shareholders' Value
by Zacks Equity Research
Altria (MO) continues to be committed toward enhancing shareholder value. The company hikes quarterly dividend rates from 70 cents per share to 80 cents.
Top Analyst Reports for JPMorgan, Altria & NextEra
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan (JPM), Altria (MO) and NextEra (NEE).
Altria (MO) Q2 Earnings Top, Smokeable Unit Hurts Revenues
by Zacks Equity Research
Altria's (MO) Q2 results benefit from growth in smokeless category. However, lower revenues in the smokeable unit are a drag.
Altria Group's (MO) Q2 Earnings Top Estimates, Sales Down Y/Y
by Zacks Equity Research
Altria (MO) has reported second quarter 2018 results wherein the bottom line beat the consensus mark.
Altria (MO) Q2 Earnings Top Estimates
by Zacks Equity Research
Altria (MO) delivered earnings and revenue surprises of 1.00% and -3.17%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Altria (MO) Q2 Earnings: Can Smokeless Products Offset Woes?
by Zacks Equity Research
Altria's (MO) Q2 results are likely to gain from rising reduced-risk tobacco products demand. However, soft cigarette volumes are a concern.
Zacks Industry Outlook Highlights: Philip Morris International, Altria Group, British American Tobacco, Imperial Tobacco Group and Turning Point Brands
by Zacks Equity Research
Zacks Industry Outlook Highlights: Philip Morris International, Altria Group, British American Tobacco, Imperial Tobacco Group and Turning Point Brands
Philip Morris (PM) Q2 Earnings: Will RRPs Steal the Show?
by Zacks Equity Research
Philip Morris' (PM) second-quarter 2018 results are likely to gain from rising RRPs demand. However, cigarette volumes will remain soft.
Can Smucker's Shareholder-Friendly Moves Help Revive Stock?
by Zacks Equity Research
Smucker (SJM) announces a quarterly dividend hike of 9% from 78 cents per share to 85 cents. This marks the company's 17th straight year of dividend hike.
Philip Morris (PM) Focused on RRPS, Inks Deal with Parallax
by Zacks Equity Research
Phillip Morris (PM) joins hands with Parallax to develop and expand reduced-risk products in order to counter strict government regulations and changing consumer trends due to health hazards.
Can RRPS, Pricing Aid Revival at Phillip Morris (PM) Stock?
by Zacks Equity Research
Regulatory hurdles and rising health consciousness have been hurting Phillip Morris (PM) cigarette volumes. However, strength in RRPs and solid pricing efforts bode well.
Should Value Investors Consider Altria (MO) Stock Now?
by Zacks Equity Research
Let's see if Altria Group, Inc. (MO) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Why Is Altria (MO) Up 2% Since Its Last Earnings Report?
by Zacks Equity Research
Altria (MO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Will Altria (MO) Stock Recover on RRPs and Shareholder Moves?
by Zacks Equity Research
Altria (MO) consistently focuses on strengthening RRPs category to offset declining cigarette volumes. Its shareholder friendly moves bode well.
The Zacks Analyst Blog Highlights: Mastercard, NVIDIA, Danaher, Automatic Data Processing and Altria
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mastercard, NVIDIA, Danaher, Automatic Data Processing and Altria